Automated RBC exchange compared to manual exchange transfusion for children with sickle cell disease is cost-effective and reduces iron overload
Automated RBC exchange compared to manual exchange transfusion for children with sickle cell disease is cost-effective and reduces iron overload
复制标题
DOI：
10.1111/trf.14575
复制
发表时间：
2018-06-01
期刊：
影响因子：
2.9
通讯作者：
Ferster, Alina
中科院分区：
文献类型：
--
作者：
Dedeken, Laurence;Phu Quoc Le;Ferster, Alina
镰状细胞病（SCD）的长期输血仍然是预防卒中和严重疾病患者的金标准疗法，尽管有足够的羟基脲治疗。本研究的目的是评估自动红细胞交换（aRBX）在既往接受过手动换血（MET）治疗的SCD患者中的安全性和有效性。研究设计和方法从2012年1月开始，体重在30 kg或以上的SCD儿童可以改用aRBX。记录MET治疗后6个月的临床、生物学和手术数据，包括费用，并与aRBX治疗第一年和第二年后的数据进行比较。转换后，中位血红蛋白S（HbS）显著增加（MET组为33.5%，aRBX组为45%; p
BACKGROUNDChronic transfusion in sickle cell disease (SCD) remains the gold standard therapy for stroke prevention and for patients with severe disease despite adequate hydroxyurea treatment. The aim of our study was to assess the safety and efficacy of automated red blood cell exchange (aRBX) in patients with SCD previously treated with manual exchange transfusion (MET). Costs related to transfusion and chelation overtime were evaluated.STUDY DESIGN AND METHODSBeginning in January 2012, children with SCD who weighed 30 kg or more on MET could switch to aRBX. Clinical, biological, and procedures' data, including costs, were recorded for the last 6 months on MET and compared to those after the first and the second year on aRBX.RESULTSTen patients switched from MET to aRBX at a median age of 11.8 years. After the switch, median hemoglobin S (HbS) increased significantly (33.5% on MET compared to 45% on aRBX; p